Here's Why GSK (GSK) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why GSK (GSK) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout
GSK agrees to buy RAPT Therapeutics for $2.2B, adding ozureprubart to its pipeline and strengthening its respiratory and immunology portfolio.
GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug
The growing scourge of food allergies drove U.K. heavyweight GSK to announce a $2.2 billion deal on Tuesday.
GSK snaps up food allergy drug specialist RAPT for $2.2bn
GSK PLC (LSE:GSK, NYSE:GSK) has struck a $2.2 billion deal to buy US biotech firm RAPT Therapeutics, adding a potential new treatment for food allergies to its pipeline. The acquisition gives GSK rights to ozureprubart, a long-acting antibody drug currently in mid-stage trials.
GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments
The drugmaker said it agreed to pay RAPT shareholders $58 per share, with $1.9 billion upfront investment in cash.
GSK to buy RAPT Therapeutics for $2.2 billion
GSK said on Tuesday that it would acquire U.S.-based RAPT Therapeutics for $2.2 billion.
Here's Why GSK (GSK) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Why GSK (GSK) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK Still Has Room To Run Despite Vaccine Cyclicality
GSK's growth is increasingly specialty-led (HIV, RI&I, oncology), not just vaccines. ViiV's long-acting injectables also tap into durable demand. Recent launches/approvals like Blenrep in r/r myeloma and depemokimab in severe asthma should extend GSK's specialty momentum. Additionally, GSK's late-stage pipeline includes 15 candidates targeting large TAMs. I like how Phase 3 CHB data is framed as a potential functional cure opportunity.
GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies
GSK's bepirovirsen hit primary endpoints in two phase III trials, boosting hopes for a functional cure in chronic hepatitis B patients.
